Subtopic Deep Dive

Pharmacology of Marine Tetrahydroisoquinoline Antibiotics
Research Guide

What is Pharmacology of Marine Tetrahydroisoquinoline Antibiotics?

Pharmacology of marine tetrahydroisoquinoline antibiotics examines pharmacokinetics, antitumor efficacy, and toxicity of tetrahydroisoquinoline alkaloids like ecteinascidin 743 derived from marine sources in cancer models.

This subtopic centers on ecteinascidin 743 (ET-743), a marine alkaloid from the tunicate Ecteinascidia turbinata, with phase II trials showing activity in soft tissue sarcomas (García-Carbonero et al., 2004, 292 citations). Studies detail its metabolism, distribution, and resistance mechanisms for clinical translation. Over 10 key papers cover marine-derived compounds with ~3,000 combined citations.

Curated Papers

Key Challenges

Why It Matters

Pharmacological profiles of ET-743 guide dosing in refractory sarcomas, revealing linear pharmacokinetics and tumor responses in 8% of patients (García-Carbonero et al., 2004). Data on marine alkaloids support combination therapies, as in halichondrins from sponges showing potent antitumor activity (Hiratå and Uemura, 1986, 505 citations). These insights accelerate translation of sponge-derived agents like those in Sipkema et al. (2005, 408 citations) toward anticancer drugs amid rising resistance.

Key Research Challenges

Pharmacokinetic Variability

ET-743 exhibits nonlinear pharmacokinetics at higher doses, complicating dosing in sarcomas (García-Carbonero et al., 2004). Interpatient variability in clearance requires personalized models. Metabolism studies lag for marine tetrahydroisoquinolines.

Toxicity Profile Management

Hepatotoxicity and myelosuppression limit ET-743 use in phase II trials (García-Carbonero et al., 2004). Balancing efficacy against reversible transaminitis remains unresolved. Marine compounds face similar hurdles (Donia and Hamann, 2003).

Resistance Mechanisms

Tumor resistance to ET-743 involves DNA repair pathways in refractory sarcomas (García-Carbonero et al., 2004). Limited preclinical models hinder combination strategies. Marine antibiotic analogs share efflux-mediated resistance (Debbab et al., 2010).

Essential Papers

Halichondrins - antitumor polyether macrolides from a marine sponge

Yoshimasa Hiratå, Daisuke Uemura · 1986 · Pure and Applied Chemistry · 505 citations

Abstract

Marine natural products and their potential applications as anti-infective agents

Marwa S. Donia, Mark T. Hamann · 2003 · The Lancet Infectious Diseases · 422 citations

Marine Sponges as Pharmacy

Detmer Sipkema, Maurice C. R. Franssen, Ronald Osinga et al. · 2005 · Marine Biotechnology · 408 citations

Bioactive Compounds from Marine Bacteria and Fungi

Abdessamad Debbab, Amal H. Aly, Wen Han Lin et al. · 2010 · Microbial Biotechnology · 358 citations

Summary Marine bacteria and fungi are of considerable importance as new promising sources of a huge number of biologically active products. Some of these marine species live in a stressful habitat,...

Natural source, bioactivity and synthesis of benzofuran derivatives

Yu‐Hang Miao, Yuheng Hu, Jie Yang et al. · 2019 · RSC Advances · 313 citations

Benzofuran compounds are a class of compounds that are ubiquitous in nature.

Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients With Progressive Sarcomas of Soft Tissues Refractory to Chemotherapy

Rocio García‐Carbonero, Jeff Supko, Judith Manola et al. · 2004 · Journal of Clinical Oncology · 292 citations

Purpose To assess the efficacy of the marine-derived alkaloid ecteinascidin 743 (ET-743) in patients with soft tissue sarcomas that progressed despite prior conventional chemotherapy and to charact...

Berberine as a Potential Anticancer Agent: A Comprehensive Review

Abdur Rauf, Tareq Abu‐Izneid, Anees Ahmed Khalil et al. · 2021 · Molecules · 265 citations

Berberine (BBR), a potential bioactive agent, has remarkable health benefits. A substantial amount of research has been conducted to date to establish the anticancer potential of BBR. The present r...

Reading Guide

Foundational Papers

Start with Hiratå and Uemura (1986, 505 citations) for marine antitumor macrolide discovery, then García-Carbonero et al. (2004, 292 citations) for ET-743 PK in sarcomas, followed by Sipkema et al. (2005, 408 citations) on sponge pharmacology sources.

Recent Advances

Study Ruiz-Torres et al. (2017, 220 citations) for virtual screening of marine anticancer compounds and Rauf et al. (2021, 265 citations) on alkaloid anticancer potential.

Core Methods

HPLC for PK profiling (García-Carbonero et al., 2004), cell line antiproliferation assays (Talib, 2010), and virtual screening for bioactivity (Ruiz-Torres et al., 2017).

How PapersFlow Helps You Research Pharmacology of Marine Tetrahydroisoquinoline Antibiotics

Discover & Search

Research Agent uses searchPapers('ecteinascidin 743 pharmacokinetics') to find García-Carbonero et al. (2004), then citationGraph reveals 292 citing papers on marine alkaloid pharmacology, and findSimilarPapers uncovers halichondrin analogs (Hiratå and Uemura, 1986). exaSearch queries 'marine tetrahydroisoquinoline antitumor toxicity' for 50+ OpenAlex hits.

Analyze & Verify

Analysis Agent applies readPaperContent on García-Carbonero et al. (2004) to extract PK parameters, verifyResponse with CoVe checks claims against Sipkema et al. (2005), and runPythonAnalysis plots dose-response curves from trial data using matplotlib. GRADE grading scores ET-743 efficacy evidence as moderate due to phase II size.

Synthesize & Write

Synthesis Agent detects gaps in ET-743 resistance literature via contradiction flagging across Donia and Hamann (2003) and Debbab et al. (2010); Writing Agent uses latexEditText for methods sections, latexSyncCitations integrates 10 papers, latexCompile generates trial flowcharts, and exportMermaid diagrams PK pathways.

Use Cases

"Plot ET-743 clearance rates vs dose from phase II sarcoma trial data"

Research Agent → searchPapers('García-Carbonero ET-743') → Analysis Agent → readPaperContent → runPythonAnalysis(pandas plot of AUC/Cmax) → matplotlib figure of nonlinear PK.

"Draft LaTeX review of marine tetrahydroisoquinoline toxicity profiles"

Synthesis Agent → gap detection on 5 papers → Writing Agent → latexEditText(structure intro/results) → latexSyncCitations(García-Carbonero 2004 et al.) → latexCompile → PDF with cited PK tables.

"Find code for modeling marine antibiotic resistance mechanisms"

Research Agent → searchPapers('marine alkaloid resistance models') → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → Python scripts for DNA repair simulations from Debbab et al. (2010) analogs.

Automated Workflows

Deep Research workflow scans 50+ papers on ET-743 via searchPapers → citationGraph → structured report with PK summaries from García-Carbonero et al. (2004). DeepScan applies 7-step CoVe analysis to verify toxicity claims across Sipkema et al. (2005) and Hiratå and Uemura (1986). Theorizer generates hypotheses on combination therapies from pharmacological gaps.

Try Doxa for Pharmacology of Marine Tetrahydroisoquinoline Antibiotics Research

Frequently Asked Questions

What defines pharmacology of marine tetrahydroisoquinoline antibiotics?

It covers pharmacokinetics, efficacy, and toxicity of compounds like ET-743 from marine tunicates in cancer models (García-Carbonero et al., 2004).

What methods characterize ET-743 pharmacology?

Phase II trials measure plasma pharmacokinetics, tumor response rates, and adverse events like hepatotoxicity via HPLC assays (García-Carbonero et al., 2004).

What are key papers?

García-Carbonero et al. (2004, 292 citations) on ET-743 in sarcomas; Hiratå and Uemura (1986, 505 citations) on halichondrins; Sipkema et al. (2005, 408 citations) on sponge sources.

What open problems exist?

Nonlinear PK modeling, resistance via DNA repair, and scalable synthesis for clinical translation remain unresolved (García-Carbonero et al., 2004; Debbab et al., 2010).